Form 4: AIM ImmunoTech CEO Acquires 85,000 Shares in Open Market Purchase

AIM ImmunoTech's CEO, Thomas K. Equels, purchased 85,000 shares of common stock at $0.199 per share on November 20, 2024.

Summary

• Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., acquired 85,000 shares of the company's common stock on November 20, 2024.
• The shares were purchased at a price of $0.199 per share.
• Following this transaction, Mr. Equels directly owns 1,637,968 shares of AIM ImmunoTech common stock.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it simply reports a transaction. The CEO's purchase could be seen as a positive sign, but it's not a major event.

Positives

• The CEO's purchase of shares could be seen as a positive sign of confidence in the company's future prospects.
• The purchase increases the CEO's direct stake in the company.

Risks

• The document does not provide any information about the company's overall financial health or future performance.
• The purchase could be interpreted as an attempt to boost investor confidence, which may not be sustainable if the company's performance does not improve.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The transaction is typical for executives who are acquiring or disposing of company stock.
• The level of detail provided is consistent with regulatory requirements.

Stakeholder Impact

• The share purchase may have a minor positive impact on shareholder sentiment.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

AIM ImmunoTech, insider trading, share purchase, CEO, Thomas K. Equels, common stock, ownership